3-Step treatment efficient for small pupils

Article

According to recently published data, a 3-step treatment protocol is an efficient way to ensure good safety margins for patients with pupils smaller than 5.5 mm

According to recently published data, a 3-step treatment protocol is an efficient way to ensure good safety margins for patients with pupils smaller than 5.5 mm undergoing femtosecond laser-assisted cataract surgery.

The study, led by Dr Ina Conrad-Hengerer (Center for Vision Science, Ruhr University Eye Hospital, Bochum, Germany), examined eyes with an intraoperative pupil size smaller than 5.5 mm to evaluate the efficacy of a 3-step treatment to achieve larger pupil sizes before femtosecond laser-assisted cataract surgery. This 3-step process consisted of initially administering intracameral epinephrine solution, then using additional viscomydriasis and thirdly implantation of a Malyugin ring pupil expander.

Out of 850 eyes that were scheduled to receive cataract surgery, 40 underwent the sequential treatments for pupil expansion. Of this group, 7% only required the first step to achieve a pupil size larger than 5.5 mm, 25% required additional voscomydriasis and 68% needed the pupil expander as well. The team found that the most frequent comorbidities were pseudoexfoliation of the lens capsule (30%) and intraoperative floppy-iris syndrome (12.5%).

Based on this study, it was deemed that the 3-step treatment allowed an increased efficiency and safety of femtosecond laser-assisted cataract surgery in eyes with a small pre-op pupil size.

For more detailed information please view the abstract from the Journal of Cataract & Refractive Surgery.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.